Skip to Content
Morningstar

Krystal Biotech Inc KRYS

Morningstar Rating
Unlock
Stock XNAS Rating as of
$162.04 +4.79 (3.05%)
View Full Chart
As of Delayed Price Post-Trading: $162.04 +0.09
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
KRYS is trading within a range we consider fairly valued.
Price
$156.90
Fair Value
$435.34
Uncertainty
Very High
1-Star Price
$561.78
5-Star Price
$28.55
Economic Moat
Lkts
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KRYS is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$157.25
Day Range
$157.92–164.73
52-Week Range
$82.09–189.97
Bid/Ask
$152.12 / $179.84
Market Cap
$4.62 Bil
Volume/Avg
223,159 / 404,631

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
89.75
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
229
Website
https://www.krystalbio.com

Comparables

Valuation

View More
Metric
KRYS
CBAY
VRDN
Price/Earnings (Normalized)
 ———
Price/Book Value
 5.9512.653.48
Price/Sales
 89.75111.012,160.78
Price/Cash Flow
 ———
Price/Earnings
KRYS
CBAY
VRDN

Financial Strength

Metric
KRYS
CBAY
VRDN
Quick Ratio
 17.3510.7017.93
Current Ratio
 17.7610.9618.26
Interest Coverage
 —−5.27−137.76
Quick Ratio
KRYS
CBAY
VRDN

Profitability

Metric
KRYS
CBAY
VRDN
Return on Assets (Normalized)
 −17.51%−30.06%−42.76%
Return on Equity (Normalized)
 −18.51%−51.97%−82.42%
Return on Invested Capital (Normalized)
 −21.22%−30.87%−50.70%
Return on Assets
KRYS
CBAY
VRDN
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRQmxjtmfzwDkb$557.8 Bil
VRTX
Vertex Pharmaceuticals IncLzlnpthmFwyksc$103.3 Bil
REGN
Regeneron Pharmaceuticals IncQqlnzrmrPclxzx$98.8 Bil
MRNA
Moderna IncWjrxmqjzRjqr$38.8 Bil
ARGX
argenx SE ADRRtlcbnppRgr$21.3 Bil
BNTX
BioNTech SE ADRLlqbybgjWfnr$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncYrhgdnwYrrcwz$18.4 Bil
BMRN
Biomarin Pharmaceutical IncHpwwngfsbMgrxvm$17.0 Bil
RPRX
Royalty Pharma PLC Class ABtrgrkqvhZpgggb$12.4 Bil
INCY
Incyte CorpNcfzzxqZgybbx$11.9 Bil

Sponsor Center